"The hepatitis C infection treatments Viekira Pak (AbbVie) and Technivie (AbbVie) may increase the risk for serious liver injury, particularly in those with underlying advanced liver disease, the US Food and Drug Administration (FDA) warned today."...
DOSAGE AND ADMINISTRATION
The recommended dosage of SOVALDI is one 400 mg tablet, taken orally, once daily with or without food [see CLINICAL PHARMACOLOGY].
Administer SOVALDI in combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of HCV. The recommended treatment regimen and duration for SOVALDI combination therapy is provided in Table 1.
For patients with HCV/HIV-1 co-infection, follow the dosage recommendations in Table 1. Refer to Drug Interactions (7) for dosage recommendations for concomitant HIV-1 antiviral drugs.
Table 1 : Recommended
Treatment Regimens and Duration
|Patient Population||Treatment Regimen||Duration|
|Genotype 1 or 4||SOVALDI + peginterferon alfaa + ribavirinb||12 weeks|
|Genotype 2||SOVALDI + ribavirinb||12 weeks|
|Genotype 3||SOVALDI + ribavirinb||24 weeks|
|a See peginterferon alfa prescribing
information for dosage recommendation for patients with genotype 1 or 4 HCV.
b Dosage of ribavirin is weight-based ( < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg). The daily dosage of ribavirin is administered orally in two divided doses with food. Patients with renal impairment (CrCl ≤ 50 mL/min) require ribavirin dosage reduction; refer to ribavirin prescribing information.
Patients with Genotype 1 HCV Who are Ineligible to Receive an Interferon-Based Regimen
SOVALDI in combination with ribavirin for 24 weeks can be considered as a therapeutic option for patients with genotype 1 infection who are ineligible to receive an interferon-based regimen [see Clinical Studies]. Treatment decision should be guided by an assessment of the potential benefits and risks for the individual patient.
Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
Administer SOVALDI in combination with ribavirin for up to 48 weeks or until the time of liver transplantation, whichever occurs first, to prevent post-transplant HCV reinfection [see Use In Specific Populations].
Dosage reduction of SOVALDI is not recommended.
If a patient has a serious adverse reaction potentially related to peginterferon alfa and/or ribavirin, the peginterferon alfa and/or ribavirin dosage should be reduced or discontinued, if appropriate, until the adverse reaction abates or decreases in severity. Refer to the peginterferon alfa and ribavirin prescribing information for additional information about how to reduce and/or discontinue the peginterferon alfa and/or ribavirin dosage.
Discontinuation Of Dosing
If the other agents used in combination with SOVALDI are permanently discontinued, SOVALDI should also be discontinued.
Severe Renal Impairment And End Stage Renal Disease
No dosage recommendation can be given for patients with severe renal impairment (estimated Glomerular Filtration Rate [eGFR] less than 30 mL/min/1.73m²) or with end stage renal disease (ESRD) due to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite [see Use in Specific Populations and CLINICAL PHARMACOLOGY].
Dosage Forms And Strengths
SOVALDI is available as a yellow-colored, capsule-shaped, film-coated tablet debossed with “GSI” on one side and “7977” on the other side. Each tablet contains 400 mg sofosbuvir.
Storage And Handling
SOVALDI tablets are yellow, capsule-shaped, film-coated tablets containing 400 mg sofosbuvir debossed with “GSI” on one side and “7977” on the other side. Each bottle contains 28 tablets (NDC 61958-1501-1), a silica gel desiccant and polyester coil with a child-resistant closure.
Store at room temperature below 30 °C (86 °F).
- Dispense only in original container
- Do not use if seal over bottle opening is broken or missing
Manufactured and distributed by: Gilead Sciences, Inc. Foster City, CA 94404. Issued: August 2015This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 3/31/2016
Additional Sovaldi Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.